The global DNA synthesizer market size was valued at USD 228.2 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 14.42% from 2023 to 2030. The increasing demand for efficient DNA synthesizers from life science laboratories, and pharmaceutical & biotechnology companies is the major factor driving the market. In addition, advancements in genomics and life sciences coupled with an increase in importance of DNA synthesizers in synthetic and molecular biology are other factors supporting market expansion.
The outbreak of COVID-19 has had both negative and positive impact on the market. The COVID-19 pandemic boosted the demand for advanced synthesizers and related products as scientists developed potential diagnostics and treatments for COVID-19. On a contrary note, the pandemic had also a negative impact on market as it disrupted the research activities and manufacturing owing to restrictions and delays in supply of raw materials. However, after mid-2021, the market has witnessed a significant growth and is anticipated to expand at moderate growth rate owing to high demand for nucleic acid synthesis platforms across various end users.
Rising demand for novel synthesis technologies and technological advancements are the major factors driving the global market. Moreover, improvements in nucleic acid synthesis methods have opened new avenues for the market participants. For instance, SYNTAX STX-100 system developed by DNA Script is the first DNA printer powered by enzymatic synthesis that enables on-demand synthesis of custom oligos in a benchtop solution. Moreover, such synthesizers are equipped with enhanced speed and flexibility modules that enable technicians to create custom oligos in in less time.
Similarly, Kilobaser RNA and DNA synthesizer is developed to provide researchers across the globe with independent and unlimited access to vital life science tools. The chip and cartridge technology permits even untrained staff to quickly complete a successful RNA or DNA synthesis. In recent times, developing synthesizers with higher yields has gained momentum hence various manufacturers are engaged in manufacturing products with higher yield. For instance, market players like Biolytic, Cytiva, CsBio have developed synthesizers with higher yield capabilities.
Moreover, increasing demand for benchtop DNA synthesizers owing to its strong promise to increase speed & efficiency of research in academic and industrial labs is projected to increase their demand even more in forecast period. Thus, the rise in demand for benchtop solutions is pushing manufacturers to develop reliable benchtop systems. For instance, in June 2021 DNA Script announced the launch of SYNTAX system, the first benchtop nucleic acid printer powered by EDS technology to bolster genomics and molecular biology workflows. Such synthesizers are anticipated to boost market growth.
Furthermore, rising efforts to lower the cost of synthesizing DNA oligonucleotides and efforts to commercialize scalable DNA synthesizers have increased in recent times. Also, the use of microfluidic/microarray oligonucleotide synthesis methods and improvements in synthetic DNA quality have made great contribution toward this goal. In addition, increased market pressures, and continued development of other efficient synthesis technologies are further projected to increase the availability of inexpensive synthesizers.
The benchtop DNA synthesizers segment dominated the market in 2022 with a market share of 72.72%. Factors such as, increasing investment in R&D, growing demand for custom DNA synthesis, and robust demand from large range of end users are projected to drive segment growth. In addition, cost effectiveness of benchtop models is another factor responsible for its higher revenue share. Benchtop models are of small size and are less expensive than those of pilot scale synthesizers thus making them more feasible for small companies and research laboratories. Moreover, these synthesizers are commonly used for applications like PCR mutagenesis, gene cloning and site directed mutagenesis. Recent advancements in synthetic biology & genetics, recent product launches, and supportive government legislation are further driving the demand for synthesizers. For instance, in May 2022 EVONETIX LTD announced that it has been granted a patent for thermally controlled DNA synthesis. The patented technology can perform nucleic acid synthesis in a benchtop synthesizer platform.
Large-scale DNA synthesizers segment is expected to expand at a significant CAGR of 12.97% during 2023-2030. Robust demand from pharmaceutical & biotechnology companies, advances in DNA sequencing technologies, and the rising need for high-throughput screening are projected to fuel segment growth. The large-scale synthesizers are being increasingly utilized for high-throughput screening in drug discovery and this is likely to provide lucrative growth opportunities for the segment.
The drug discovery and development segment was the leading segment in 2022 with a revenue share of 48.11%. Wide application of DNA synthesizers in drug discovery, technology advancements, rising adoption of high-throughput technology, and presence of large number of market players with robust product portfolio are projected to fuel segment growth. Moreover, rising demand for advanced synthesis tools from drug companies to facilitate efficiency is another factor supporting segment expansion. For instance, in June 2022, Twist Bioscience announced its plans to remove limits on drug discovery with DNA synthesis platform. This helped company to expand its drug development capabilities.
The genetic engineering segment is projected to exhibit the fastest CAGR of 15.11% over the forecast period. Advancements in genetic engineering, rising availability of gene editing techniques like CRISPR/Cas9, and rising funding for commercializing novel interventions in genetic engineering are fueling segment uptake. Availability of several compact and laboratory scale synthesizers is also expected to boost the segment growth.
The pharmaceutical and biotechnology companies segment held the highest revenue share of 52.37% in 2022. Majority of pharma and biotech companies use synthetic DNA for developing novel genetic therapies, and for drug discovery process. Thus, the demand for synthesizers from biotechnology and pharmaceutical companies is projected to increase significantly in coming years due to rising need for precision medicine and novel therapeutic approaches. Moreover, leading market players emphasize on development, and implementation of novel platforms that can foster synthesis is another factor propelling segment growth. For instance, in February 2023 AstraZeneca automated its DNA synthesis capabilities to save cost and time. Also, according to Telesis Bio, automating DNA synthesis can boost drug discovery process. In addition, the company also mentioned that by automation the pharma and biotech firms can leverage and expand their pipeline.
The academic and research institutes segment is expected to expand at the fastest CAGR of 15.21% from 2023 to 2030. Growing areas of interest in research, ongoing efforts to develop novel synthesizers with higher yield capabilities, and collaboration between companies and research institutions are the factors expected to be responsible for growth of the segment. For instance, in January 2020, Evonetix collaborated with imec to foster chip-based technology manufacturing for third generation nucleic acid synthesis platform.
North America accounted for the largest market share of 39.22% in 2022. The presence of large number of market players and various developments done by them is the key factor driving the region’s growth. Moreover, technological advancements, high investment in R&D, and rising demand for innovative synthesizers are other factors supporting regional market. Furthermore, the investments by market participants in the region is on the rise. For instance, in March 2022 Molecular Assemblies, Inc. raised USD 25.8 million series B financing to start key customer program for fully enzymatic DNA synthesis.
Asia Pacific is estimated to expand at a fastest CAGR of 15.92% from 2023 to 2030. This can be attributed to the surge in interest in synthetic biology research coupled with rising R&D efforts for the development of effective therapeutics. Moreover, APAC has a significant incidence of diseases due to lifestyle changes. Improving healthcare infrastructure, entry of large biotechnology organizations, and rising investments of market players in this region are also expected to contribute to the growth in demand for synthesizers.
Several major companies are vying for a higher market share in the very competitive DNA synthesizer market. Major key companies are undertaking strategic activities like mergers, acquisitions, and alliances to elevate their market position. For instance, in March 2023, Elegen launched its ENFINIA DNA platform for rapid DNA synthesis, which may lead to the development of new synthesizers based on this technology in the near future. Some of the key players in the DNA synthesizer market include:
K&A Labs GmbH
Biolytic Lab Performance Inc.
Market size value in 2023
USD 258.7 million
Revenue forecast in 2030
USD 664.2 million
CAGR of 14.42% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Type, application, end use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait
Key companies profiled
Danaher; Twist Bioscience; Kilobaser; LGC Limited; CSBio; K&A Labs GmbH; DNA Script; OligoMaker ApS; PolyGen GmbH; Biolytic Lab Performance Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global DNA synthesizer market report on the basis of type, application, end use and region:
Type Scope Outlook (Revenue, USD Million, 2018 - 2030)
Benchtop DNA Synthesizers
Large-scale DNA Synthesizers
Application Scope Outlook (Revenue, USD Million, 2018 - 2030)
Drug Discovery & Development
End use Scope Outlook (Revenue, USD Million, 2018 - 2030)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global DNA synthesizer market was estimated at USD 228.2 million in 2022 and is expected to reach USD 258.7 million in 2023.
b. The global DNA synthesizer market is expected to grow at a compound annual growth rate of 14.42% from 2023 to 2030 to reach USD 664.2 million by 2030.
b. North America dominated the DNA synthesizer market with a share of 39.22% in 2022. Technological advancements, high investment in R&D, and rising demand for innovative synthesis platforms are factors is fueling the regional market.
b. Some key players operating in the DNA synthesizer market include, Danaher, Twist Bioscience, Kilobaser, LGC Limited, CSBio, K&A Labs GmbH, DNA Script., OligoMaker ApS, PolyGen GmbH, Biolytic Lab Performance Inc. among others.
b. The increasing demand for efficient DNA synthesizers from life science laboratories, and pharmaceutical & biotechnology companies is the major factor driving the DNA synthesizer market. In addition, advancements in genomics and life sciences coupled with an increase in importance of DNA synthesis in synthetic & molecular biology are other factors supporting market expansion.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."